Delcath Systems, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| DCTH | TLSI | IMCR | PMRA.F | GUD.TO | IDYA | |
|---|---|---|---|---|---|---|
| Market cap | 514.24M | 239.53M | 1.51B | 1.17B | 1.11B | 3.12B |
| P/E (TTM) | 1,482.0 | — | — | 17.3 | 75.3 | — |
| Forward P/E | 348.7 | -15.6 | -37.7 | — | 43.5 | -7.9 |
| Price/book | 4.2 | 36.4 | 3.6 | 5.0 | 1.4 | 2.9 |
| Dividend yield | — | — | — | 1.54% | — | — |
| 1-year change | +65.90% | −21.80% | −2.50% | −11.53% | +92.81% | +5.63% |
| Today | +2.92% | +11.78% | −2.66% | +6.01% | +0.36% | +3.29% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All DCTH news ›Delcath Systems: Intriguingly Poised Ahead Of Q3 Earnings
Seeking Alpha - Delcath Systems, which has outperformed other Russell 2000 stocks and healthcare equipment makers by 3x and 8x this year, is due to publish Q3 results on the 9th of Nov. - The probability of a topline beat looks high, while…
Contrasting Delcath Systems (NASDAQ:DCTH) and Pulmonx (NASDAQ:LUNG)
Posted by Kim Johansen on Nov 2nd, 2026 Delcath Systems (NASDAQ:DCTH – Get Free Report) and Pulmonx (NASDAQ:LUNG – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies…
Delcath Systems: Rosalind amends 9.9% stake disclosure
Delcath Systems Inc (DCTH) is an interventional oncology company focused on liver cancers, offering HEPZATO KIT and CHEMOSAT hepatic delivery systems. - [SCHEDULE 13D/A] DELCATH SYSTEMS, INC. Amended Major Shareholder Report Delcath…
Delcath Systems: Rosalind distributes 27,502 shares
The distribution satisfied limited partners' redemption requests for no consideration. Rosalind also converted 36.27 preferred shares on October 13, 2026. - [Form 4] DELCATH SYSTEMS, INC. Insider Trading Activity Delcath Systems: Rosalind…
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma
HEPZATO KIT is the only FDA approved liver-directed therapy to treat metastatic uveal melanoma Approval includes treatment naïve and previously treated patients and is not limited by HLA genotype Delcath to hold Business Update Call on…
Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
RITZ® Brand Introduces Gluten Free Crackers in Original Flavor Plug Power Appoints Dr. Lee Sweetland as Global Engineering Industrialization Lead Eos Energy Enterprises Announces Preliminary Third Quarter 2026 Revenue Growth and Continued…
Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)
Feb 22, 2024, 17:00 ET Sites included on the Locator are accepting inquiries from patients or their physicians seeking potential treatment with HEPZATO KIT. These sites either have or expect to have completed all training and internal…
Head to Head Review: Delcath Systems (NASDAQ:DCTH) and Green Thumb Industries (OTCMKTS:GTBIF)
Posted by Kim Johansen on Oct 8th, 2026 Green Thumb Industries (OTCMKTS:GTBIF – Get Free Report) and Delcath Systems (NASDAQ:DCTH – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net2
- themarketsdaily.com2
- seekingalpha.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.